Učitavanje...

TCR-Engineered, Customized, Antitumor T Cells for Cancer Immunotherapy: Advantages and Limitations

The clinical outcome of the traditional adoptive cancer immunotherapy approaches involving the administration of donor-derived immune effectors, expanded ex vivo, has not met expectations. This could be attributed, in part, to the lack of sufficient high-avidity antitumor T-cell precursors in most c...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:ScientificWorldJournal
Glavni autor: Chhabra, Arvind
Format: Artigo
Jezik:Inglês
Izdano: TheScientificWorldJOURNAL 2011
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5720046/
https://ncbi.nlm.nih.gov/pubmed/21218269
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1100/tsw.2011.10
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!